Epidermal growth factor receptor mutations: Effect on volume doubling time of non-small-cell lung cancer patients

Journal of Thoracic Oncology

Volumn 9, Issue 9, 2014, Pages 1340-1344

  Nakamura, Ryota ^a   Inage, Yoshihisa ^a   Tobita, Rika ^a   Mori, Kazuko ^a   Numata, Takeshi ^a   Yanai, Hidetoshi ^a   Endo, Takeo ^a   Ohtani, Haruo ^a   Satoh, Hiroaki ^b   Yuzawa, Kenji ^a   Koizumi, Masanori ^a   Ueki, Hamaichi ^a  

^a NATIONAL HOSPITAL ORGANIZATION MITO MEDICAL CENTER   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Epidermal growth factor receptor mutation; Non small cell lung cancer; Volume doubling time

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; DNA;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SIZE; CANCER SURGERY; COMPUTED TOMOGRAPHY SCANNER; EXON; FEMALE; FOLLOW UP; GENE MUTATION; HISTOPATHOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MUTATOR GENE; ONCOLOGICAL PARAMETERS; POINT MUTATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SMOKING HABIT; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; TIME; VOLUME DOUBLING TIME; WEDGE RESECTION; CARCINOMA, NON-SMALL-CELL LUNG; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; GENETICS; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PROGNOSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84906319119     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000022     Document Type: Article

References (27)

1. Detterbeck FC, Gibson CJ. Turning gray: the natural history of lung cancer over time. J Thorac Oncol 2008;3:781-792.
2. UsudaK, Sato Y, Sagawa M, et al. Tumor doubling time and prognostic assessment of patients with primary lung cancer. Cancer 1994;74:2239-2244.
3. Kanashiki M, Tomizawa T, Yamaguchi I, et al. Volume doubling time of lung cancers detected in a chest radiograph mass screening program: Comparison with CT screening. Oncol Lett 2012;4:513-516.
4. Steele JD, Buell P. Asymptomatic solitary pulmonary nodules. Host survival, tumor size, and growth rate. J Thorac Cardiovasc Surg 1973;65:140-151.
5. Hasegawa M, Sone S, Takashima S, et al. Growth rate of small lung cancers detected on mass CT screening. Br J Radiol 2000;73:1252-1259.
6. Aoki T, Nakata H, Watanabe H, et al. Evolution of peripheral lung adenocarcinomas: CT findings correlated with histology and tumor doubling time. AJR Am J Roentgenol 2000;174:763-768.
7. Xu DM, van der Zaag-Loonen HJ, Oudkerk M, et al. Smooth or attached solid indeterminate nodules detected at baseline CT screening in the NELSON study: cancer risk during 1 year of follow-up. Radiology 2009;250:264-272.
8. Veronesi G, Maisonneuve P, Bellomi M, et al. Estimating overdiagnosis in low-dose computed tomography screening for lung cancer: a cohort study. Ann Intern Med 2012;157:776-784.
9. Xu DM, Gietema H, de Koning H, et al. Nodule management protocol of the NELSON randomised lung cancer screening trial. Lung Cancer 2006;54:177-184.
10. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
11. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500.
12. Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 2007;98:1817-1824.
13. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004;64:8919-8923.
14. Yano M, Sasaki H, Kobayashi Y, et al. Epidermal growth factor receptor gene mutation and computed tomographic findings in peripheral pulmonary adenocarcinoma. J Thorac Oncol 2006;1:413-416.
15. Hsu KH, Chen KC, Yang TY, et al. Epidermal growth factor receptor mutation status in stage I lung adenocarcinoma with different image patterns. J Thorac Oncol 2011;6:1066-1072.
16. Beasley MB, Brambilla E, Travis WD. The 2004 World Health Organization classification of lung tumors. Semin Roentgenol 2005;40:90-97.
17. Edge SB, Byrd DR, Compton CC. Lung AJCC Cancer Staging Manual, 7th Ed. New York, NY: Springer, 2010:253-270.
18. Lindell RM, Hartman TE, Swensen SJ, et al. Five-year lung cancer screening experience: CT appearance, growth rate, location, and histologic features of 61 lung cancers. Radiology 2007;242:555-562.
19. Schwartz M. A biomathematical approach to clinical tumor growth. Cancer 1961;14:1272-1294.
20. Yoshida K, Yatabe Y, Park JY, et al. Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer. J Thorac Oncol 2007;2:22-28.
21. Lillington GA. Management of solitary pulmonary nodules. Dis Mon 1991;37:271-318.
22. Yoshida Y, Kokubu A, Suzuki K, et al. Molecular markers and changes of computed tomography appearance in lung adenocarcinoma with ground- glass opacity. Jpn J Clin Oncol 2007;37:907-912.
23. Glynn C, Zakowski MF, Ginsberg MS. Are there imaging characteristics associated with epidermal growth factor receptor and KRAS mutations in patients with adenocarcinoma of the lung with bronchioloalveolar features? J Thorac Oncol 2010;5:344-348.
24. Tilanus-Linthorst MM, Obdeijn IM, Hop WC, et al. BRCA1 mutation and young age predict fast breast cancer growth in the Dutch, United Kingdom, and Canadian magnetic resonance imaging screening trials. Clin Cancer Res 2007;13:7357-7362.
25. Wu SG, Hu FC, Chang YL, et al. Frequent EGFR mutations in nonsmall cell lung cancer presenting with miliary intrapulmonary carcinomatosis. Eur Respir J 2013;41:417-424.
26. Sekine A, Kato T, Hagiwara E, et al. Metastatic brain tumors from non- small cell lung cancer with EGFR mutations: distinguishing influence of exon 19 deletion on radiographic features. Lung Cancer 2012;77:64-69.
27. Ashraf H, Dirksen A, Loft A, et al. Combined use of positron emission tomography and volume doubling time in lung cancer screening with low- dose CT scanning. Thorax 2011;66:315-319.